

Genomic biomarker-based treatment for solid tumours overview


NICE Pathways bring together everything NICE says on a topic in an interactive flowchart. NICE Pathways are interactive and designed to be used online.

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

<http://pathways.nice.org.uk/pathways/genomic-biomarker-based-treatment-for-solid-tumours>

NICE Pathway last updated: 12 August 2020

This document contains a single flowchart and uses numbering to link the boxes to the associated recommendations.



1 Genomic biomarker-based treatment for solid tumours

No additional information

2 NTRK fusion-positive solid tumours

Entrectinib

The following recommendations are from [NICE technology appraisal guidance on entrectinib for treating NTRK fusion-positive solid tumours](#).

Entrectinib is recommended for use within the Cancer Drugs Fund as an option for treating NTRK fusion-positive solid tumours in adults and children 12 years and older if:

- the disease is locally advanced or metastatic or surgery could cause severe health problems and
- they have not had an NTRK inhibitor before and
- they have no satisfactory treatment options.

It is recommended only if the conditions in the [managed access agreement](#) for entrectinib are followed.

This recommendation is not intended to affect treatment with entrectinib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop. For children and young people, this decision should be made jointly by the clinician and the child or young person or their parents or carers.

See [why we made the recommendations on entrectinib](#).

NICE has written [information for the public on entrectinib](#).

The point at which to use entrectinib in solid tumour treatment pathways is uncertain. See [sections 3.5](#) and [4.1](#) of the guidance for more details.

Larotrectinib

The following recommendations are from [NICE technology appraisal guidance on larotrectinib](#)

for treating NTRK fusion-positive solid tumours.

Larotrectinib is recommended for use within the Cancer Drugs Fund as an option for treating NTRK fusion-positive solid tumours in adults and children if:

- the disease is locally advanced or metastatic or surgery could cause severe health problems and
- they have no satisfactory treatment options.

It is recommended only if the conditions in the [managed access agreement](#) for larotrectinib are followed.

This recommendation is not intended to affect treatment with larotrectinib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop. For children and young people, this decision should be made jointly by the clinician and the child or young person or their parents or carers.

See [why we made the recommendations on larotrectinib](#).

NICE has written [information for the public on larotrectinib](#).

The point at which to use larotrectinib in solid tumour treatment pathways is uncertain. See [sections 3.5](#) and [4.1](#) of the guidance for more details.

3 NICE Pathways on solid tumours

See the following NICE Pathways on solid tumours:

- [Advanced breast cancer](#)
- [Bladder cancer](#)
- [Brain tumours and metastases](#)
- [Cervical cancer](#)
- [Colorectal cancer](#)
- [Endocrine cancers](#)
- [Gastrointestinal cancers](#)
- [Liver cancers](#)
- [Lung cancer](#)

- [Melanoma](#)
- [Oesophageal and gastric cancer](#)
- [Ovarian cancer](#)
- [Pancreatic cancer](#)
- [Prostate cancer](#)
- [Renal cancer](#)
- [Sarcoma](#)
- [Upper aerodigestive tract cancer](#).

4 NICE Pathway on ensuring adults have the best experience of NHS services

[See Patient experience in adult NHS services](#)

Glossary

NTRK

neurotrophic tyrosine receptor kinase

Sources

[Entrectinib for treating NTRK fusion-positive solid tumours \(2020\) NICE technology appraisal guidance 644](#)

[Larotrectinib for treating NTRK fusion-positive solid tumours \(2020\) NICE technology appraisal guidance 630](#)

Your responsibility

Guidelines

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian.

Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should [assess and reduce the environmental impact of implementing NICE recommendations](#) wherever possible.

Technology appraisals

The recommendations in this interactive flowchart represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take these recommendations fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this interactive flowchart is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Commissioners and/or providers have a responsibility to provide the funding required to enable the recommendations to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.

Medical technologies guidance, diagnostics guidance and interventional procedures guidance

The recommendations in this interactive flowchart represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take these recommendations fully into account. However, the interactive flowchart does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Commissioners and/or providers have a responsibility to implement the recommendations, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this interactive flowchart should be interpreted in a way that would be inconsistent with compliance with those duties.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.